

NEWS RELEASE

RECORDATI: PUBLICATION OF DOCUMENTS

Milan, 13th May 2024 – Please be informed that **the Interim Report at 31st March 2024**, representing additional voluntary financial reporting, approved by the Board of Directors on 9th May 2024, as per the press release issued on the same date, today has been made available to the public at the Company's registered office, on the <u>Company's website</u> and on the "<u>1INFO</u>" storage mechanism.

Please also be informed that, pursuant to Article 125-quater of the Legislative Decree 58/98, **the minutes of the Ordinary General Meeting of the Shareholders** held on 22nd April 2024 have been made available today to the public at the Company's registered office, on the <u>Company's website</u> and on the "1INFO" storage mechanism.

Recordati (Reuters RECI.MI, Bloomberg REC IM) is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271) uniquely structured to bring treatment across specialty and primary care, consumer healthcare, and rare diseases. We believe that health, and the opportunity to live life to the fullest, is a right, not a privilege. We want to support people in unlocking the full potential of their lives. We have fully integrated operations across research & development, chemical and finished product manufacturing through to commercialisation and licensing. Established in 1926, Recordati operates in approximately 150 countries across EMEA, Americas and APAC regions. At the end of 2023, Recordati employed over 4,450 people and consolidated revenue of € 2,082.3 million. For more information, please visit www.recordati.com

Investor Relations
Eugenia Litz
+44 7824 394 750
investorelations@recordati.it

Investor Relations
Lucia Abbatantuoni
+39 337 1025645
investorelations@recordati.it

Media Relations Brunswick:
Barbara Scalchi / Andrea Mormandi
+39 02 9288 6200
recordati@brunswickgroup.com